Skip to content
Brand AI

Actavis

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile2 entries

  1. 2022

    UK hydrocortisone tablet pricing case

    The UK Competition and Markets Authority confirmed findings that Actavis had abused a dominant position by charging excessive and unfair prices for hydrocortisone tablets and by entering agreements that impeded potential competition. The findings concerned the supply of medicines to the National Health Service and covered conduct associated with substantial price increases over the preceding years.

    Source

  2. 2020

    Astellas files patent-infringement complaint against pharmaceutical companies

    Lawsuit filed

    Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies. The complaint alleged that the companies' proposed generic versions of Myrbetriq would infringe the '780 patent. The plaintiffs sought court relief. The allegations are claims made in the complaint and have not been established as findings.

    Source excerpt

    • At the District Court of Delaware on Tuesday, Astellas Pharma Inc. (API), Astellas Ireland Co. Ltd. (AICL), and Astellas Pharma Global Development (APGD) filed a complaint against 21 pharmaceutical companies alleging patent infringement.
    • The defendants are as follows: Sandoz Inc., Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA Inc., Apotex Inc., Apotex Corp., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Sawai Pharmaceutical Co. Ltd., Sawai USA Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Huahai US Inc., Solco Healthcare US LLC, Windlas Healthcare Pvt. Ltd., Windlas Biotech Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. (doing business as Zydus Cadila), Lupin Ltd., and Lupin Pharmaceuticals, Inc.
    • The patent in question, deemed the ’780 patent, corresponds to APGD’s Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.
    Source